Mural Oncology Statistics
Total Valuation
Mural Oncology has a market cap or net worth of $36.21 million. The enterprise value is -$35.71 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mural Oncology has 17.32 million shares outstanding. The number of shares has increased by 2.15% in one year.
| Current Share Class | 17.32M |
| Shares Outstanding | 17.32M |
| Shares Change (YoY) | +2.15% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 33.95% |
| Float | 12.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.87 |
| Quick Ratio | 2.71 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.46 |
Financial Efficiency
Return on equity (ROE) is -111.75% and return on invested capital (ROIC) is -60.66%.
| Return on Equity (ROE) | -111.75% |
| Return on Assets (ROA) | -52.60% |
| Return on Invested Capital (ROIC) | -60.66% |
| Return on Capital Employed (ROCE) | -229.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.27M |
| Employee Count | 116 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.46% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -40.46% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 2.62 |
| Relative Strength Index (RSI) | 52.96 |
| Average Volume (20 Days) | 116,018 |
Short Selling Information
The latest short interest is 425,813, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 425,813 |
| Short Previous Month | 435,901 |
| Short % of Shares Out | 2.46% |
| Short % of Float | 3.51% |
| Short Ratio (days to cover) | 3.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -135.69M |
| Pretax Income | -147.15M |
| Net Income | -147.15M |
| EBITDA | -131.93M |
| EBIT | -135.69M |
| Earnings Per Share (EPS) | -$8.59 |
Full Income Statement Balance Sheet
The company has $77.09 million in cash and $5.17 million in debt, giving a net cash position of $71.92 million or $4.15 per share.
| Cash & Cash Equivalents | 77.09M |
| Total Debt | 5.17M |
| Net Cash | 71.92M |
| Net Cash Per Share | $4.15 |
| Equity (Book Value) | 58.78M |
| Book Value Per Share | 3.40 |
| Working Capital | 53.14M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$130.01 million and capital expenditures -$52,000, giving a free cash flow of -$130.06 million.
| Operating Cash Flow | -130.01M |
| Capital Expenditures | -52,000 |
| Free Cash Flow | -130.06M |
| FCF Per Share | -$7.51 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mural Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.15% |
| Shareholder Yield | -2.15% |
| Earnings Yield | -406.40% |
| FCF Yield | -359.20% |
Analyst Forecast
The average price target for Mural Oncology is $6.00, which is 187.08% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 187.08% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |